Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now? [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
In this article, we will summarize the bulls' thesis on TVTX. Travere Therapeutics, Inc.'s share was trading at $40.29 as of April 20th. TVTX's forward P/E was 54.35 , respectively according to Yahoo Finance. Jim Cramer Discusses DaVita's (DVA) Share Price Movement robina-weermeijer--szKjHyPq28-unsplash Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. TVTX is approaching a critical commercial inflection point as adoption of its lead therapy Filspari accelerates, evidenced by a record 908 new patient start forms in Q4 2025, signaling that nephrologists are increasingly prioritizing long-term kidney preservation despite REMS-related friction. Read More: 15 AI Stocks That Are Quietly Making Investors Rich Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential Filspari's dual endothelin and angiotensin receptor blockade
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Purespring announces publication of notable study highlighting an under recognised genetic driver of adult-onset FSGS, in particular in US and UK populations [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics to Report First Quarter 2026 Financial ResultsBusiness Wire
- Travere Therapeutics (TVTX) had its "buy" rating reaffirmed by Guggenheim.MarketBeat
- Is It Time To Reassess Travere Therapeutics (TVTX) After Its Recent Price Surge [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics: Still Undervalued Post FSGS Approval [Seeking Alpha]Seeking Alpha
TVTX
Earnings
- 2/19/26 - Beat
TVTX
Sec Filings
- 4/23/26 - Form 4
- 4/22/26 - Form 144
- 4/16/26 - Form 4
- TVTX's page on the SEC website